Poster
48
(#48) Persistent Benefit of Pharmacogenomic Testing on Remission and Response Rates in Patients With Major Depressive Disorder
Psych Congress 2025
Abstract: In patients with major depressive disorder (MDD), achieving remission often involves a lengthy trial-and-error process to identify effective medication. Pharmacogenomic (PGx) testing is a prescribing tool that has been shown to improve remission and response rates for MDD patients, but evidence describing its impact over time is limited. This study was a post hoc analysis of the PRIME Care (Precision Medicine in Mental Health Care) randomized clinical trial that compared PGx-guided treatment with usual care among veterans with depression. Multivariate Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations between study arm (PGx-guided treatment or usual care) and the first instance of response or remission as assessed by the Patient Health Questionnaire-9 (PHQ-9) scale. Of the 1,974 veterans in the PRIME Care trial, 1,764 (90.7%) had sufficient visit data to be included in this analysis. Patients who received PGx-guided treatment had higher rates of remission (HR [95% CI] = 1.27 [1.05, 1.53]; p = 0.015) and response (HR [95% CI] = 1.21 [1.05, 1.40]; p = 0.010) relative to patients receiving usual care. Schoenfeld residuals tests of the study arm variable were not statistically significant for remission (p = 0.931) or response (p = 0.112), providing no evidence that the benefit due to PGx-guided treatment changed over the 24-week period. In conclusion, PGx-guided treatment led to faster remission and response in patients with MDD, and this benefit persisted over six months with no evidence of diminishing.
Short Description: This study was a post hoc analysis of the PRIME Care (Precision Medicine in Mental Health Care) randomized clinical trial that compared pharmacogenomic (PGx)-guided treatment with usual care among veterans with depression. Patients who received PGx-guided treatment had higher rates of remission and response at any trial timepoint relative to patients receiving usual care, and the benefit of PGx-guided treatment persisted over the 6-month trial period with no evidence of diminishing.
Name of Sponsoring Organization(s): Myriad Genetics
Short Description: This study was a post hoc analysis of the PRIME Care (Precision Medicine in Mental Health Care) randomized clinical trial that compared pharmacogenomic (PGx)-guided treatment with usual care among veterans with depression. Patients who received PGx-guided treatment had higher rates of remission and response at any trial timepoint relative to patients receiving usual care, and the benefit of PGx-guided treatment persisted over the 6-month trial period with no evidence of diminishing.
Name of Sponsoring Organization(s): Myriad Genetics
